A novel BCR::ABL1 I502T mutation associated with acquired asciminib resistance in CML
Authors:
- 1 October 2026
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 171
Abstract
No abstract availableFunding Information
- National Cancer Institute (S10OD025183)
- National Cancer Institute (R50 R50CA211108)
This publication has 11 references indexed in Scilit:
- 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemiaLeukemia, 2025
- Asciminib in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2024
- The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminibLeukemia, 2024
- The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinaseLeukemia Research, 2020
- Response and Resistance to BCR-ABL1-Targeted TherapiesCancer Cell, 2020
- Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 MutantsCancer Cell, 2019
- Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABLJournal of Molecular Graphics and Modelling, 2019
- Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminibLeukemia, 2017
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1Nature, 2017
- The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibilityNature Communications, 2014